Prognostic value of telomere attrition in patients with aplastic anemia

International Journal of Hematology

Volumn 97, Issue 5, 2013, Pages 553-557

  Scheinberg, Phillip ^a  

^a HOSPITAL SÃO JOSÉ   (Brazil)

Author keywords

Aplastic anemia; Clonal evolution; Immunosuppressive therapy; Pancytopenia; Relapse; Telomeres

Indexed keywords

ALEMTUZUMAB; ANDROGEN; CYCLOSPORIN; DANAZOL; ELTROMBOPAG; GAMMA INTERFERON; HEAT SHOCK PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; THYMOCYTE ANTIBODY;

ANDROGEN THERAPY; ANEUPLOIDY; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CHROMOSOMES AND CHROMOSOMAL PHENOMENA; CLONAL EVOLUTION; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC PREDISPOSITION; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM SURVIVAL; LOSS OF FUNCTION MUTATION; MOLECULAR CLONING; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROGNOSIS; PROTEIN EXPRESSION; RETICULOCYTE COUNT; TELOMERE; TELOMERE ATTRITION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANEMIA, APLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; RECURRENCE; TELOMERASE; TELOMERE; TREATMENT OUTCOME;

EID: 84878014343     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1332-x     Document Type: Article

References (49)

1. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120:1185-96.
2. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematol Am Soc Hematol Educ Progr. 2012;2012:292-300.
3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509-19.
4. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130-5.
5. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931-4.
6. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430-8.
7. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012;119:345-54.
8. Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998;100:393-400.
9. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133:622-7.
10. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99:3129-35.
11. Verma A, Deb DK, Sassano A, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002;168:5984-8.
12. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100:1185-91.
13. Takami A, Nakao S, Tatsumi Y, et al. High inducibility of heat shock protein 72 (hsp72) in peripheral blood mononuclear cells of aplastic anaemia patients: a reliable marker of immune-mediated aplastic anaemia responsive to cyclosporine therapy. Br J Haematol. 1999;106:377-84.
14. Sloand E, Scheinberg P, Fenlon E, et al. Monosomy 7 detected by FISH at disease presentation is a marker for non-response to immunosuppression. ASH Annu Meet Abstr. 2007;110:1697.
15. Nakao S, Sugimori C, Yamazaki H. Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure. Int J Hematol. 2006;84:118-22.
16. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206-16.
17. Yoshida N, Yagasaki H, Takahashi Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. Br J Haematol. 2008;142:427-35.
18. Gluckman E, Devergie A, Poros A, Degoulet P. Results of immunosuppression in 170 cases of severe aplastic anaemia. Report of the European Group of Bone Marrow Transplant (EGBMT). Br J Haematol. 1982;51:541-50.
19. Chang MH, Kim KH, Kim HS, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2010;84:154-9.
20. Afable MG 2nd, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011;96:1269-75.
21. Yoshida N, Yagasaki H, Hama A, et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2011;96:771-4.
22. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11-9.
23. Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011;52:726-35.
24. Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102-4.
25. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008;153:814-9.
26. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049-54.
27. Fuhrer M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. Klin Padiatr. 1998;210:173-9.
28. Huang IA, Jaing TH, Yang CP, et al. Single-Center Experience: immunosuppressive therapy as frontline treatment for 33 children with acquired severe aplastic anemia. Pediatr Hematol Oncol. 2009;26:487-95.
29. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood. 2008;111:4446-55.
30. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361:2353-65.
31. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582-92.
32. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97:895-900.
33. Fogarty PF, Yamaguchi H, Wiestner A, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003;362:1628-30.
34. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352:1413-24.
35. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304:1358-64.
36. Ma H, Zhou Z, Wei S, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE. 2011;6:e20466.
37. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20:1238-50.
38. Willeit P, Willeit J, Mayr A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010;304:69-75.
39. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet. 2002;32:280-4.
40. Risques RA, Vaughan TL, Li X, et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2007;16:2649-55.
41. Calado RT, Cooper JN, Padilla-Nash HM, et al. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia. 2012;26:700-7.
42. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 2001;107:67-77.
43. Baird DM, Rowson J, Wynford-Thomas D, Kipling D. Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet. 2003;33:203-7.
44. Dumitriu B, Ueda Y, Kajigaya S, Townsley DM, Young NS. Very short telomeres of peripheral blood leukocytes precede clinical progression to myelodysplasia with monosomy 7 in aplastic anemia patients. ASH Annu Meet Abstr. 2012;120:1265.
45. Gardner FH, Juneja HS. Androstane therapy to treat aplastic anaemia in adults: an uncontrolled pilot study. Br J Haematol. 1987;65:295-300.
46. Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114:2236-43.
47. Chen J, Desierto MJ, Dent JJ, et al. Androgen treatment mitigates hematopoietic cell telomere attrition in vivo. ASH Annu Meet Abstr. 2012;120:516.
48. Ziegler P, Schrezenmeier H, Akkad J, et al. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. Ann Hematol. 2012;91:1115-20.
49. Townsley DM, Dumitriu B, Kajigaya S, Calado RT, Scheinberg P, Young NS. Clinical and genetic heterogeneity of telomere diseases. ASH Annu Meet Abstr. 2012;120:2373.